Standard Chemical & Pharmaceutical Past Earnings Performance
Past criteria checks 3/6
Standard Chemical & Pharmaceutical has been growing earnings at an average annual rate of 19.3%, while the Pharmaceuticals industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 11.9% per year. Standard Chemical & Pharmaceutical's return on equity is 14.2%, and it has net margins of 13.4%.
Key information
19.3%
Earnings growth rate
19.3%
EPS growth rate
Pharmaceuticals Industry Growth | 18.5% |
Revenue growth rate | 11.9% |
Return on equity | 14.2% |
Net Margin | 13.4% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
If You Like EPS Growth Then Check Out Standard Chem & Pharm (TPE:1720) Before It's Too Late
Apr 13A Look At The Fair Value Of Standard Chem & Pharm CO., LTD. (TPE:1720)
Mar 14Does Standard Chem & Pharm (TPE:1720) Have A Healthy Balance Sheet?
Mar 01Should Standard Chem & Pharm (TPE:1720) Be Disappointed With Their 11% Profit?
Feb 16Is Standard Chem & Pharm CO., LTD.'s (TPE:1720) 4.3% Dividend Worth Your Time?
Feb 03Standard Chem & Pharm CO., LTD.'s (TPE:1720) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Jan 19Here's Why I Think Standard Chem & Pharm (TPE:1720) Might Deserve Your Attention Today
Jan 04Is Standard Chem & Pharm CO., LTD. (TPE:1720) Popular Amongst Insiders?
Dec 22A Look At The Fair Value Of Standard Chem & Pharm CO., LTD. (TPE:1720)
Dec 08Standard Chem & Pharm (TPE:1720) Seems To Use Debt Rather Sparingly
Nov 26Revenue & Expenses BreakdownBeta
How Standard Chemical & Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 6,240 | 835 | 1,200 | 266 |
30 Sep 23 | 6,231 | 848 | 1,148 | 252 |
30 Jun 23 | 6,135 | 863 | 1,174 | 246 |
31 Mar 23 | 6,107 | 853 | 1,151 | 250 |
31 Dec 22 | 5,851 | 815 | 1,117 | 252 |
30 Sep 22 | 5,501 | 813 | 499 | 256 |
30 Jun 22 | 5,072 | 734 | 988 | 249 |
31 Mar 22 | 4,740 | 672 | 970 | 243 |
31 Dec 21 | 4,604 | 707 | 949 | 242 |
30 Sep 21 | 4,489 | 694 | 980 | 237 |
30 Jun 21 | 4,413 | 649 | 983 | 239 |
31 Mar 21 | 4,372 | 612 | 973 | 233 |
31 Dec 20 | 4,305 | 524 | 986 | 227 |
30 Sep 20 | 4,219 | 461 | 962 | 220 |
30 Jun 20 | 4,223 | 455 | 975 | 224 |
31 Mar 20 | 4,125 | 425 | 979 | 225 |
31 Dec 19 | 3,937 | 376 | 968 | 226 |
30 Sep 19 | 3,905 | 374 | 981 | 229 |
30 Jun 19 | 3,769 | 383 | 966 | 217 |
31 Mar 19 | 3,656 | 383 | 955 | 216 |
31 Dec 18 | 3,573 | 374 | 933 | 225 |
30 Sep 18 | 3,480 | 329 | 927 | 228 |
30 Jun 18 | 3,624 | 366 | 951 | 236 |
31 Mar 18 | 3,702 | 367 | 942 | 248 |
31 Dec 17 | 3,849 | 363 | 968 | 240 |
30 Sep 17 | 3,898 | 393 | 942 | 252 |
30 Jun 17 | 3,761 | 347 | 918 | 248 |
31 Mar 17 | 3,725 | 319 | 935 | 243 |
31 Dec 16 | 3,674 | 340 | 917 | 241 |
30 Sep 16 | 3,635 | 338 | 931 | 250 |
30 Jun 16 | 3,529 | 323 | 918 | 247 |
31 Mar 16 | 3,374 | 325 | 876 | 238 |
31 Dec 15 | 3,321 | 348 | 873 | 239 |
30 Sep 15 | 3,280 | 345 | 890 | 221 |
30 Jun 15 | 3,275 | 349 | 866 | 233 |
31 Mar 15 | 3,304 | 381 | 853 | 239 |
31 Dec 14 | 3,296 | 374 | 828 | 243 |
30 Sep 14 | 3,203 | 334 | 803 | 253 |
30 Jun 14 | 3,125 | 292 | 797 | 243 |
31 Mar 14 | 3,069 | 277 | 823 | 235 |
31 Dec 13 | 3,054 | 299 | 806 | 226 |
30 Sep 13 | 3,207 | 331 | 809 | 218 |
30 Jun 13 | 3,277 | 350 | 839 | 209 |
Quality Earnings: 1720 has high quality earnings.
Growing Profit Margin: 1720's current net profit margins (13.4%) are lower than last year (13.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1720's earnings have grown by 19.3% per year over the past 5 years.
Accelerating Growth: 1720's earnings growth over the past year (2.4%) is below its 5-year average (19.3% per year).
Earnings vs Industry: 1720 earnings growth over the past year (2.4%) exceeded the Pharmaceuticals industry -15%.
Return on Equity
High ROE: 1720's Return on Equity (14.2%) is considered low.